Trial Profile

Randomized, Open Label, Phase 3 Trial Of Erlotinib Alone Or In Combination With Cp 751,871 In Patients With Advanced Non Small Cell Lung Cancer Of Non Adenocarcinoma Histology

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 20 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Figitumumab (Primary) ; Erlotinib
Indications Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Pharmacogenomic; Registrational; Therapeutic Use
Acronyms ADVIGO
Sponsors Pfizer

Most Recent Events

14 Oct 2021 This trial has been completed in France (End Date: 26 Apr 2012), according to European Clinical Trials Database record.
21 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
29 May 2012 Actual patient number changed from 582 to 583 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com